Skip to content

Sign Up

or

Forgot Password?

Don't have an account?

Sign Up

or

By submitting my information, I agree to the Privacy Policy and Terms of Service.

Already have an account?

Moderna revises COVID-19 vaccine approval to 2021 spring, stock price slumps

Moderna revises vaccines approval to 2021 spring, stock price slumps
Jordan Major

Moderna CEO Stéphane Bancel has confirmed that the company’s coronavirus vaccine won’t be ready before the November 3rd U.S presidential elections. According to Bancel, the vaccine will be ready for mass public distribution until next year’s spring. 

Initially, Moderna had claimed that it will seek emergency approval of its vaccines as early as November 1st. The development also deals a blow to U.S President Donald Trump‘s promise of availing a vaccine before the elections.

Speaking on Wednesday, Bancel noted that Moderna will seek approval for the general population use towards the end of January. If the vaccine passes all the tests, it will be available for full approval by at least March.  According to Bancel:

“I think a late [first quarter], early [second quarter] approval is a reasonable timeline, based on what we know from our vaccine,”

According to the latest trial tests, the results were the same among all participants. The results were the same as getting a high dose flu vaccine. The vaccine is currently in the third stage of the clinical trial. 

Safe tests are now the central focus for many governments as governments attempt to get back to normal operations. Notably, China and Russia have already begun the mass administration of their vaccines. 

Despite President Trump’s assertions, experts have warned against rushing the vaccines due to political reasons. Similarly, the Center for Disease Control has noted that the mass administration of the vaccine will not be available until next year. 

At the same time, the United States Food and Drug Administration has affirmed that the vaccines’ approval will be guided by science only. 

Following the revision of vaccine timelines, Moderna shares dropped by $4 to just over $70 per share. 

Watch video: Moderna CEO says vaccine will not be ready before US election.

Best Crypto Exchange for Intermediate Traders and Investors

  • Invest in cryptocurrencies and 3,000+ other assets including stocks and precious metals.

  • 0% commission on stocks - buy in bulk or just a fraction from as little as $10. Other fees apply. For more information, visit etoro.com/trading/fees.

  • Copy top-performing traders in real time, automatically.

  • eToro USA is registered with FINRA for securities trading.

30+ million Users worldwide
Securities trading offered by eToro USA Securities, Inc. (“the BD”), member of FINRA and SIPC. Cryptocurrency offered by eToro USA LLC (“the MSB”) (NMLS: 1769299) and is not FDIC or SIPC insured. Investing involves risk, and content is provided for educational purposes only, does not imply a recommendation, and is not a guarantee of future performance. Finbold.com is not an affiliate and may be compensated if you access certain products or services offered by the MSB and/or the BD

Read Next:

Finance Digest

By subscribing you agree with Finbold T&C’s & Privacy Policy

Related posts

Services

IMPORTANT NOTICE

Finbold is a news and information website. This Site may contain sponsored content, advertisements, and third-party materials, for which Finbold expressly disclaims any liability.

RISK WARNING: Cryptocurrencies are high-risk investments and you should not expect to be protected if something goes wrong. Don’t invest unless you’re prepared to lose all the money you invest. (Click here to learn more about cryptocurrency risks.)

By accessing this Site, you acknowledge that you understand these risks and that Finbold bears no responsibility for any losses, damages, or consequences resulting from your use of the Site or reliance on its content. Click here to learn more.